Navigation Links
Women's cancer outcomes improved by surgical evaluation
Date:2/12/2009

SAN ANTONIO, Texas Many women scheduled to undergo hysterectomy for pre-cancerous cell changes actually need a more comprehensive surgery, something they should discuss with a gynecologic oncologist, say researchers at the University of Alabama at Birmingham (UAB).

If seen by a specialist, it should be recommended they undergo a procedure that focuses on lymph nodes and other organs not involved in a traditional hysterectomy, said Warner Huh, M.D., a researcher at the UAB Comprehensive Cancer Center.

The finding was presented at the Society of Gynecologic Oncologists' 2009 Annual Meeting on Women's Cancer in San Antonio.

"Given the high rate of endometrial cancer, these data strongly suggest all women who have abnormal bleeding and a diagnosis of pre-cancerous lesions of the uterus should be evaluated by a gynecologic oncologist," Huh said.

Huh and his research team analyzed medical records of more than 3,322 patients treated at seven community hospitals across Alabama from 1999 to 2008. They specifically looked women diagnosed with pre-cancerous changes called complex atypical hyperplasia (CAH).

Of patients who underwent a traditional hysterectomy, about half were found to have invasive endometrial cancer after their procedure. That means too many hysterectomy patients should've had a more comprehensive cancer surgery, something a gynecologist oncologist is trained to do, Huh said.

To avoid unwanted outcomes, women diagnosed with CAH should be referred to a gynecologic oncologist for evaluation, he said.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Page: 1

Related medicine news :

1. Womenshealthchannel Enhancements Support Pregnant Teens
2. Pediatric Hodgkins disease survivors face increased breast cancer risk
3. Nanoparticle smart bomb targets drug delivery to cancer cells
4. Tanger Outlet Centers Introduced the Tanger Cure Card & Raised $30,000 to Fight Cancer
5. Drug Inhibits Colon Cancer in Mice
6. Researchers discover metabolite linked to aggressive prostate cancer
7. Survey of metabolites finds new prostate cancer marker
8. Ronald P. Stanton gives $50 million toward cancer care at NewYork-Presbyterian Hospital
9. Electronic Health Record Advances Patient-Centered Cancer Care at Cancer Treatment Centers of America
10. Urine Test May One Day Predict Prostate Cancer
11. Electronic Health Record Advances Patient-Centered Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name ... New York, NY, on December 3rd, to benefit Holy Name Medical Center's programs ... event, which raised over $1 million - the largest event in the Center's ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare Properties ... by an affiliate of Seavest, has won a prestigious national healthcare real estate ... ambulatory care center (ACC) was named “Best New Development, MOBs and Other Outpatient ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, ... Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related to ... prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 with ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has ... report to their offering. ... The global travel vaccines market to grow at ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the sales of various ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
Breaking Medicine Technology: